Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data61
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)49
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)37
Update on mGlu4 modulator patents: 2017 to present35
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)32
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
FAK inhibitors in cancer, a patent review – an update on progress31
The role of patent analysis in target selection30
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)30
Caspase inhibitors: a review on recently patented compounds (2016–2023)29
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)23
A patent review of MAPK inhibitors (2018 – present)23
An updated patent review of AKT inhibitors (2020 – present)23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review20
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)20
Inhibition of GTPase KRAS G12D : a review of patent literature20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
0.31026315689087